A Star Is Born? HERCULES Data Shine At ASH For Ablynx's Caplacizumab

Strong Phase III HERCULES data mean Ablynx's caplacizumab is likely to sail through regulatory proceedings next year, becoming the first approved therapy for the rare blood disease, acquired thrombotic thrombocytopenic purpura.

SC1712_constellation Hercules_687159919_1200.jpg
Written in the stars: approvals expected in 2018 follwoing strong data for Ablynx's caplacizumab in HERCULES trial • Source: Shutterstock

Ablynx NV has presented more positive data for caplacizumab - which looks set to become the first drug approved for rare blood clotting disorder, acquired thrombotic thrombocytopenic purpura (aTTP) - that highlight potential selling points likely to win over payers if the drug is successful with regulators.

Analysts have called caplacizumab a "game changer" for Ablynx since the company reported the positive data for the drug this week. The additional data from the Phase III HERCULES trial were published on Dec

More from Strategy

More from Business